16 July 2021

ImmuPharma PLC

("ImmuPharma" or the "Company")

BOARD APPOINTMENT

ImmuPharma PLC (LSE:IMM) | Euronext Growth Brussels: ALIMM),  the specialist drug discovery and development company, is delighted to announce the appointment of Dr Tim Franklin, Chief Operating Officer, to the Board of Directors.

Tim has worked with ImmuPharma for over three years, initially as a consultant and more recently was appointed as Chief Operating Officer in November 2020.  Tim's key responsibilities include working closely with ImmuPharma's clinical team and scientific advisors, as the Company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.

In addition, Tim will lead the relationship with Avion Pharmaceuticals, as the Company advances Lupuzor™ through its Phase 3 trial and regulatory processes involved in the ultimate approval of the drug.

Tim has over 30 years' experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Commenting on the appointment, Tim McCarthy, Chairman said: "It is a pleasure to welcome Tim onto the Board of Directors. Tim has made an invaluable contribution to ImmuPharma over the last three years. During this time, he played a key role in negotiations, which resulted in the successful conclusion of the licensing deal with Avion Pharmaceuticals, our partner for Lupuzor™, which is now close to embarking on its international Phase 3 trial. His extensive pharmaceutical and capital markets experience will contribute enormously to the team as we look to move into the next phase of our journey for the Company."

End

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Timothy Gary Franklin (aged 57).

Dr Tim Franklin currently holds 1.5 million options over ordinary shares in the Company.

Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Dr Tim Franklin.

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.